210 related articles for article (PubMed ID: 23830367)
1. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
Iwase R; Haruki K; Fujiwara Y; Furukawa K; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K
J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
Uwagawa T; Chiao PJ; Gocho T; Hirohara S; Misawa T; Yanaga K
Anticancer Res; 2009 Aug; 29(8):3173-8. PubMed ID: 19661331
[TBL] [Abstract][Full Text] [Related]
3. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
Fujiwara Y; Shiba H; Iwase R; Haruki K; Furukawa K; Uwagawa T; Misawa T; Ohashi T; Yanaga K
J Am Coll Surg; 2013 Feb; 216(2):320-32.e3. PubMed ID: 23219147
[TBL] [Abstract][Full Text] [Related]
5. Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells.
Takada N; Sugano H; Shirai Y; Saito N; Hamura R; Taniai T; Uwagawa T; Yanaga K; Ikegami T; Ohashi T; Eto K
PLoS One; 2021; 16(9):e0257019. PubMed ID: 34473771
[TBL] [Abstract][Full Text] [Related]
6. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
Yu Y; Wang J; Xia N; Li B; Jiang X
Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
[TBL] [Abstract][Full Text] [Related]
7. α-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.
Shi Y; Fan Y; Hu Y; Jing J; Wang C; Wu Y; Geng Q; Dong X; Li E; Dong D
J Cell Mol Med; 2020 Jan; 24(1):760-771. PubMed ID: 31762191
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
Furukawa K; Iida T; Shiba H; Fujiwara Y; Uwagawa T; Shimada Y; Misawa T; Ohashi T; Yanaga K
Oncol Rep; 2010 Oct; 24(4):843-50. PubMed ID: 20811662
[TBL] [Abstract][Full Text] [Related]
9. Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB.
Zhang DC; Liu JL; Ding YB; Xia JG; Chen GY
Acta Pharmacol Sin; 2013 Feb; 34(2):301-8. PubMed ID: 23274410
[TBL] [Abstract][Full Text] [Related]
10. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Holcomb BK; Yip-Schneider MT; Waters JA; Beane JD; Crooks PA; Schmidt CM
J Gastrointest Surg; 2012 Jul; 16(7):1333-40. PubMed ID: 22618517
[TBL] [Abstract][Full Text] [Related]
11. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
Wang Y; Wu X; Zhou Y; Jiang H; Pan S; Sun B
Cancer Prev Res (Phila); 2016 Mar; 9(3):234-44. PubMed ID: 26667450
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
14. Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-κB.
Yang MH; Lee KT; Yang S; Lee JK; Lee KH; Moon IH; Rhee JC
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1743-51. PubMed ID: 22699931
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.
Shirai Y; Shiba H; Iwase R; Haruki K; Fujiwara Y; Furukawa K; Uwagawa T; Ohashi T; Yanaga K
Cancer Lett; 2016 Jan; 370(2):177-84. PubMed ID: 26546875
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.
Furukawa K; Ohashi T; Haruki K; Fujiwara Y; Iida T; Shiba H; Uwagawa T; Kobayashi H; Yanaga K
Cancer Lett; 2011 Jul; 306(1):92-8. PubMed ID: 21482023
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
[TBL] [Abstract][Full Text] [Related]
18. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice.
Mita Y; Ajiki T; Kamigaki T; Okazaki T; Hori H; Horiuchi H; Hirata K; Fujita T; Fujimori T; Kuroda Y
Ann Surg Oncol; 2007 Apr; 14(4):1374-80. PubMed ID: 17235714
[TBL] [Abstract][Full Text] [Related]
20. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
